医药行业跟踪报告：MNC重金加码中国创新药，中国IO2.0双抗出海迈出关键一步

Investment Rating - The report assigns an investment rating of "Outperform" for the pharmaceutical sector, indicating a relative performance better than the market index [2]. Core Insights - The pharmaceutical sector experienced a market adjustment with the SW Pharmaceutical Biotechnology Index declining by 3.31% during the week of January 26 to February 1, 2026, underperforming the CSI 300 Index which increased by 0.08% [2]. - AstraZeneca plans to invest over 100 billion RMB (approximately 15 billion USD) in China by 2030, focusing on drug production and R&D, aligning with the "Healthy China 2030" initiative [2]. - The FDA has accepted the overseas listing application for the innovative PD-1/VEGF dual antibody, Ivoris, marking a significant step in global market expansion for Chinese innovations [2]. Summary by Sections Market Performance - The pharmaceutical sector's performance was mixed, with blood products and vaccines showing relative strength, while offline pharmacies and hospitals faced declines of 4.83% and 4.47%, respectively [2]. Investment Opportunities - The report highlights continued optimism for Chinese innovative drugs going global, particularly in areas such as ADCs, dual antibodies, small nucleic acids, and weight loss drugs [2]. - Key companies to watch include InnoCare Pharma, 3SBio, WuXi AppTec, Maiwei Biotech, Kelun-Biotech, and CanSino Biologics [2]. Strategic Collaborations - AstraZeneca's collaboration with CSPC Pharmaceutical Group involves a strategic partnership in weight management, with potential milestone payments reaching up to 17.3 billion USD [2]. - The report emphasizes the importance of upcoming data updates from major conferences like JPM and ASCO for investment catalysts [2].